Description du projet
Un nouveau traitement combiné contre la tuberculose
La tuberculose reste la maladie infectieuse la plus meurtrière au monde, et la tuberculose multirésistante constitue une grave menace pour la santé dans le monde. Les options de traitement sont limitées et souvent associées à de nombreux effets indésirables des médicaments. L’objectif général du projet RespiriTB, financé par l’UE, est de trouver de nouveaux médicaments candidats pour un traitement combiné efficace contre la tuberculose et la tuberculose multirésistante. La combinaison de médicaments ciblera le métabolisme énergétique de Mycobacterium tuberculosis (Mtb), en utilisant des inhibiteurs de la voie respiratoire Mtb récemment découverts. Elle ciblera également les facteurs de l’hôte qui sont essentiels pour la survie intracellulaire de Mtb. Le projet présente un plan global visant à trouver de nouvelles stratégies pour lutter contre la tuberculose, raccourcir la durée du traitement et réduire l’incidence de la résistance aux médicaments.
Objectif
Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Thus, there is an acute need for the development of a novel combination regimen with an indication for effective, shorter, and safer treatment of all forms of TB. The overall objective of RESPIRI-TB is to find new drug candidates as potential components of a new, more efficient combination drug regimen against TB that is less prone to resistance and allows shortening of treatment duration for TB, and multidrug-resistant TB. Such a drug combination will synergistically target the energy metabolism of Mtb or complementary targets. To achieve this, we will advance recently discovered inhibitors of the Mtb respiratory pathway. In addition, we will target the Mtb specific molecular mechanism that reduces reactive oxygen species in the cell. Finally, we will also target host-factors that are essential for the intracellular survival of Mtb. Together, we present a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce chances of drug resistance.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
2333 ZA Leiden
Pays-Bas